MDoutlook announces the launch of its latest syndicated research study in which U.S. and international oncologists provide their perspectives on who, why and how the industry demonstrates leadership in advancing cancer treatment and care.
The Pharmaceutical Company Ranking in Oncology addresses and provides:
- what the oncologist community views as best practices by pharma in support, engagement and communication in improving cancer patient treatment and care
- who and what exemplifies leadership in addressing today’s top cancer care challenges
- additional specific oncologist views on pharma breast cancer leadership
- a self-assessment benchmarking tool for improving and enhancing current oncologist community outreach and support
- an optional study on oncologist views and usage of recently-launched breast cancer treatment therapies
Additional study details:
> comprehensive quantitative and qualitative research conducted:
> more than 100 medical oncologists interviewed via online (U.S. and Europe-based)
> top international experts recognized for their leadership in oncology interviewed by phone
> oncologist ranking criteria across 9 categories including innovation, sales reps and MSL support
> analysis available by U.S. and E.U. regions
> option to purchase entire syndicated study or customized reports tied to specific data within the study
> entire syndicated study and requested customized reports available within 3 days of purchase
> please click here to read more study details and how to order
Contact John Kane at firstname.lastname@example.org or at +1.814.325.9945 for inquiries about and/or to purchase this research.
NOW AVAILABLE: Impact of New Breast Cancer Data Announcements at ESMO 2017
Newly published syndicated report available on the impact of new breast cancer data presented at ESMO 2017:
> compare sponsored symposia
> get a read on expert sessions focused on HER2+ve adjuvant and neo-breast cancer treatments
> gain insights on poster and presentations on breast cancer at ESMO 2017, including perceptions of current breast cancer biosimilars
> assess awareness and impact of clinical trial data in specific breast cancer studies
> please click on this link to learn more
At MDoutlook, we focus on providing actionable insights to our clients. These insights can provide valuable data to improve market share and compare and contrast our client’s products to those of their competition. Below is a case study outlining the main reasons taxanes are not considered for use following paclitaxel treatment in ovarian cancer.
Customer: Global pharmaceutical company expanding their disease portfolio into new therapeutic areas.
Challenge: Client needed to compare and contrast treatment decision drivers between competitive therapies as input for their clinical development and commercialization planning.
Unique MDoutlook proposition:
- Develop comprehensive questionnaire to address both quantitative treatment market share analysis while differentiating qualitative decision driver attributes often retrieved by different research methodologies (e.g. qualitative)
- Panel Composition: 100 screened ovarian cancer treaters
- Comparative Analysis:
- By competitive therapies
- Academic vs. community practice
- Actionable insights to guide patient segmentation, commercial positioning and messaging
- Robust and projectable quantitative market share analysis
- Sophisticated qualitative insights generated by a quantitative study methodology that increased the study efficiencies and shortened the study timeline
Send an email to email@example.com to learn more.
Whether it is the impact of the future usage in ALK positive lung cancer in first line of alectinib over the current standard of care or the potential use of DNA Disease repair in advanced BRCA-related breast cancer, many innovations in cancer treatment will be having an impact on the treatment protocols moving forward.
After every major conference, MDoutlook provides valuable insights to our clients on the impact of new data presented. With the 17 ASCO conference behind us, we will be generating syndicated reports in the following therapy areas:
• Hematology: AML, CML
• Hepato-Cellular Carcinoma
• Non-small cell lung cancer
• Renal Cell Carcinoma
If you would like to purchase or receive more details about our post conference syndicated reports, contact us by calling +1.404.496.4136 or dropping us a line here.
Earlier this month our President and Founder Jan Heybroek was interviewed by Lynn Fosse, Senior Editor of CEO/CFO Magazine. The interview discusses the concept and vision behind MDoutlook, how MDoutlook delivers value to its clients and the on-going engagement with oncologists and ThoughtLeaders.
“We have developed a platform and a network of more than one hundred thousand cancer physicians that we have identified, researched and validated as being responsible and active in the management of cancer…We invite these physicians, typically by survey emails, to participate in research. Physicians respond to us in a secure environment to the questions that we have developed with our client partners. We have MDs and PhDs on the staff who review these responses and pull together reports that we then share back with both sponsors and participants.”, Jan said.
You can read the full interview here: CEOCFO Magazine Interview with Jan Heybroek.
For more information about MDoutlook, contact us at firstname.lastname@example.org or +1.404.496.4136.
While typically, you would assume that oncologists would prefer face to face interactions with ThoughtLeaders, our poll demonstrated different results.
When asked, “What is the preferred method of interacting with ThoughtLeaders?” over half of those polled responded via computer.
Remember this statistic the next time you consider flying a ThoughtLeader to a remote location to meet with cancer treaters.
To see how MDoutlook is able to provide you further actionable intelligence, email me at email@example.com
Assumptions have been made for years that nationally recognized ThoughtLeaders are substantially more effective at modifying treatment behavior than regional or local experts, thus commanding a larger honorarium.
However, in MDoutlook’s new Insights & Influence Report on the U.S. market, one section analyzes the impact that national, regional, and local ThoughtLeaders, as well as peer groups, have on influencing oncologists’ treatment behavior. This report has been developed in partnership with Medallion Healthcare.
The results show, while national U.S. ThoughtLeaders do have more overall influence, the gap between the national experts and the regional experts is found to be much smaller than anticipated.
MDoutlook’s Insights & Influence Report is a comprehensive survey of oncologists which measures the impact of various intelligence strategies employed and how large of an impact those strategies have on influencing oncologists’ treatment behaviors. If you are interested in purchasing the full report, click here.
At MDoutlook, we can leverage our proprietary database of over 12,000 validated oncology ThoughtLeaders and panel of 110,000+ cancer treaters globally to assist you. Click here to learn more.
To accommodate our growth, MDoutlook has moved its headquarters to a new office around the block from our old one.
The new address is:
45 Technology Parkway, South, Suite 220
Norcross, GA 30092
Phone and fax remain the same. Click here for the location on the map and directions.
If you are in the neighborhood, stop by for a cup of coffee. We will gladly show you our new office!
How has the 58th ASH Annual Meeting been received by the oncology community? How much does attendance at this (or other major meetings) impact the uptake of the new clinical information? MDoutlook’s® innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego will help you understand these questions, in addition to the specific clinical topics covered by our research.
Building on over 40 analyses covering ASH, ASCO, SABCS, ESMO and ESH for nearly a decade, this is our second report from the 2016 ASH meeting. We are proud to support the entire cancer community with this research.
This OncoPoll™ report focuses on the development of CAR-T Cell therapies for a variety of hematologic malignancies. It examines a number of target antigen + malignancy therapies in development plus some additional thoughts meaning on their impact in oncologist’s practice today – although none are yet commercially available.
Our analyses of the meeting impact on US oncologists (study sample n=100, see graphic) this year compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources as well treatment setting.
- US oncologists are relatively aware of and see the development of CAR-T Cell therapies as very important to the B-lineage malignancies for which they are currently being studied. The leading CAR-T Cell approach, CD19-targeted in B-Cell acute lymphocytic leukemia, slightly leads the pack in both awareness and expected importance
- Even though CAR-T Cell therapies are not yet commercially available, oncologists are up-to-date about them in their routine practices:
- Referral of patients to the clinical trials is common, overall averaging about 4 per respondent over the past year
- Oncologists, especially ASH attendees, frequently are being asked about these approaches by their patients, even outside of the clinical trial setting
- The involvement of NIH in the development of CAR-T Cell therapies is seen as a positive for US oncologists
- Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend recognize the clinical importance to a similar extent as those who did attend
Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on CAR-T-Cell Therapies.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review.
To discuss your oncology and disease intelligence needs, please contact us at firstname.lastname@example.org or +1.404.496.4136.
MDoutlook® proudly continues our innovative initiative of syndicated research analyzing the clinical impact of new data presented at the 58th ASH Annual Meeting in San Diego. Supporting the entire cancer community and building on over 40 analyses covering ASH since 2008, this is our first report from the 2016 meeting.
This OncoPoll™ focuses on B-cell lymphomas. It covers the choice between Rituxan® and Gazyva® in the front line setting for different lymphomas and the use of Rituxan and Revlimid® in the maintenance setting.
Our analyses of the meeting impact on US oncologists this year ((study sample n=100, see graphic) compares the different impact of the conference on those who attended the conference versus those who learned about the news from other sources:
• Oncologists see the comparison of the anti-CD20 antibodies Rituxan and Gazyva, in combination with chemotherapy in the front line setting for follicular and diffuse large B-cell lymphomas, as important clinical developments
• Overall usage of Gazyva in the front-line setting is expected to rise at the expense of Rituxan
• Use of maintenance strategies, with Rituxan in mantle cell lymphoma and Revlimid in CLL, is expected to continue to rise in popularity for hematologic malignancies
• Attendance at the meeting is not necessary for this new information to impact clinical practices. While initial awareness of the information may be lower, upon learning about it, the physicians who did not attend are just as, if not more likely to change their practices to integrate the clinical improvements
Download your complimentary copy of our report MDoutlook OncoPoll report from ASH 2016 on NHL-B-Cell.
MDoutlook continues its commitment to all stakeholders involved in the management of cancer to provide actionable and timely insight. As in previous years, we work with Oncology Business Review to share this important research with the cancer community.
To discuss your oncology and disease intelligence needs, please contact us at email@example.com or +1.404.496.4136.